Joinn Laboratories Expects 2025 Profit to More Than Triple Year on Year

MT Newswires Live
01/21

Joinn Laboratories (China) (HKG:6127) said it expects its 2025 attributable profit to more than triple year on year, according to a Hong Kong bourse filing Tuesday.

Shares of the drug research company gained nearly 1% in late morning trade Wednesday.

The firm expects 232.6 million yuan to 348.9 million yuan in 2025 profit, up 214% to 371% when compared to 2024.

Revenue for the year is expected to decrease 14% to 22% year-on-year to 1.57 billion yuan to 1.74 billion yuan.

The firm expects to report its results by the end of March.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10